Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB-C354 |
Synonyms | |
Therapy Description |
Limited information is currently available on BGB-C354, a putative antibody-drug conjugate (ADC) targeting CD276 (B7-H3) (Aug 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-C354 | BGB C354|BGBC354 | CD276 Antibody 16 | Limited information is currently available on BGB-C354, a putative antibody-drug conjugate (ADC) targeting CD276 (B7-H3) (Aug 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06422520 | Phase I | BGB-C354 BGB-C354 + Tislelizumab | A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |